Rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and obstetric antiphospholipid syndrome (APS), frequently affect women of childbearing age [1, 3, 5]. In the past, individuals with these chronic autoimmune conditions were often advised against becoming pregnant due to high concerns regarding maternal and fetal health risks [4]. However, modern medical advancements and collaborative care approaches have significantly changed how these pregnancies are managed, allowing many patients to experience successful outcomes [4].
Understanding Risks and Disease Flares
Women diagnosed with RA or SLE may experience disease flares during pregnancy, which can introduce complex clinical challenges [1, 2]. Active maternal disease, particularly in the months leading up to conception, substantially increases the likelihood of these flares [3]. Uncontrolled inflammation can subsequently lead to adverse pregnancy outcomes, such as preeclampsia, preterm delivery, and infants who are small for gestational age [1, 2, 3]. Because of these risks, achieving stable disease control prior to conception is a primary goal in reproductive health management [1, 2, 7].
Preconceptional Counseling and Risk Stratification
Comprehensive preconceptional counseling is an essential step for patients with rheumatic conditions [5, 8]. This evaluation involves a detailed risk stratification that assesses current disease activity, specific organ involvement, antibody profiles, and any existing health comorbidities [5]. Healthcare providers also review safe contraceptive methods and discuss family planning well before pregnancy occurs [8]. For individuals with obstetric APS, specific medical interventions, such as anticoagulation therapy, must be implemented during pregnancy to protect both maternal and fetal health [1, 2].
Medication Safety and Management
A critical aspect of managing rheumatic diseases during pregnancy and lactation is optimizing medication regimens [1, 2, 8]. While many antirheumatic medications are safe and compatible for use during pregnancy, others must be avoided or substituted to prevent potential harm to the developing fetus [1, 2, 7]. Ongoing monitoring of disease activity helps clinicians adjust treatments effectively, ensuring that inflammation remains suppressed without introducing unnecessary risks [5, 8].
Collaborative Care and Monitoring
Successful management relies heavily on close clinical monitoring throughout pregnancy and the postpartum period [5]. A collaborative care model that brings together rheumatologists and obstetricians ensures that patients receive specialized, well-rounded attention [4]. Through careful oversight, risk assessment, and personalized treatment plans, individuals living with rheumatic diseases can navigate pregnancy safely and optimize health outcomes for both mother and child [4, 8].
Sources
- [1] Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Obstetric Antiphospholipid Syndrome
- [2] Pregnancy and Management in Women with Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Obstetric Antiphospholipid Syndrome
- [3] The Course of Rheumatic Diseases During Pregnancy
- [4] Evaluation and management of systemic lupus erythematosus and rheumatoid arthritis during pregnancy
- [5] Reproductive Health in RA, Lupus, and APS
- [6] Outcomes in Children Born to Women with Rheumatic Diseases
- [7] Rheumatic diseases and pregnancy
- [8] Optimizing reproductive health management in lupus and Sjogren's syndrome